| Dr Lori Ward, PHARM D | |
|
2200 Malcolm Ave, Newport, AR 72112-3668 | |
| (870) 523-9472 | |
| Not Available |
| Full Name | Dr Lori Ward |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 2200 Malcolm Ave, Newport, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194314955 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PD08473 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lori Ward, PHARM D 2200 Malcolm Ave Ste D, Newport, AR 72112-3697 Ph: (870) 523-9472 | Dr Lori Ward, PHARM D 2200 Malcolm Ave, Newport, AR 72112-3668 Ph: (870) 523-9472 |
News Archive
A multi-disciplinary team representing the schools of Medicine, Nursing and Social Work at the University of Louisville, as well as clinical pastoral education programs in three Louisville hospitals, has been awarded a grant of $1,518,092 from the National Institutes of Health that will fund the development, implementation and evaluation of an interdisciplinary oncology palliative care education program. Work related to the project will begin immediately.
Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.
Chemotherapy is one of the most common treatments for cancer patients. However, many patients suffer from serious side-effects and a large proportion does not respond to the treatment. Researchers from the Biotech Research and Innovation Centre (BRIC) and Center for Healthy Aging, University of Copenhagen, now show that the gene FBH1 helps turn up the effect of chemotherapy.
Cells don't like to be alone. In the early stages of tumor formation, a cell might be pushed out of its normal home environment due to excessive growth. But a cell normally responds to this homeless state by dismantling its nucleus, packing up its DNA, and offering itself to be eaten by immune system cells. Simply put, the homeless cell kills itself. This process, known as apoptosis, typically stops potential cancer cells before they have a chance to proliferate.
Blood and urine markers can indicate which patients with an abrupt kidney injury following heart surgery will experience progressive kidney problems, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.
› Verified 5 days ago
William Eric Shoffner, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1117 Mclain St Ste 400, Newport, AR 72112 Phone: 870-523-5555 Fax: 870-523-6337 | |
Amanda Kay Quick, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1211 Highway 367 N, Newport, AR 72112 Phone: 870-523-2383 | |
Dr. Michael Bryant Jr., Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1211 Highway 367 N, Newport, AR 72112 Phone: 870-523-2383 | |
Dr. Karen Chaplain, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2401 Malcolm Ave, Newport, AR 72112 Phone: 870-217-0170 | |
Dr. Jennifer Lanelle Wynn, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1303 Mclain St, Newport, AR 72112 Phone: 870-523-5888 Fax: 870-523-9980 | |
Mary Kathryn Davis, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2200 Malcolm Ave Ste D, Newport, AR 72112 Phone: 870-523-9472 Fax: 870-523-9364 |